Microbot Medical Secures Israeli Distribution Deal for LIBERTY Robotic System

  • Microbot Medical signed a three-year exclusive distribution agreement with Medtechnica Ltd. for the LIBERTY Endovascular Robotic System in Israel.
  • The company received regulatory approval from the Israeli Ministry of Health's AMAR Division in May 2026.
  • Initial orders from Medtechnica Ltd. are anticipated during Q4 2026.
  • LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.

This deal marks Microbot Medical's strategic move to engage with distributors in developed markets, preparing for potential future market entry outside the U.S. The agreement with Medtechnica Ltd. aligns with the company's goal to scale operations and expand manufacturing capacity to meet increasing demand for the LIBERTY System. The Israeli market serves as a testing ground for the company's ability to navigate regulatory environments and establish a foothold in international markets.

Market Expansion
How Microbot Medical will leverage this deal to enter other international markets beyond Israel.
Regulatory Dynamics
Whether the company can maintain regulatory approvals in new markets while scaling operations.
Execution Risk
The pace at which Microbot Medical can fulfill initial orders and meet growing demand.